Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Co.'s pipeline includes product candidates that utilize its understanding of the tumor microenvironment, including both angiogenesis-targeted agents and immune-oncology focused agents. These product candidates are designed to support critical components required for an anti-tumor response to cancer. These include modulation of the microvasculature via angiogenesis-targeted agents, and induction of an immune response via activators on effector cells in the tumor microenvironment. The CMPX average annual return since 2021 is shown above.
The Average Annual Return on the CMPX average annual return since 2021 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether CMPX average annual return since 2021 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the CMPX average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|